

# Iconovo 2021 Capital Markets Day

Date: May 26, 2021

Time: 13.00-15.30

Live broadcast with moderator: Amanda Termén

## Agenda:

### 1. Introduction, Company, Future Strategy overview – Johan Wäborg

- Introduction to Iconovo
- Platform & project overview
- Our business model
- Sustainability targets
- Our new strategy

### 2. Generics business – Dr Orest Lastow, Roger Lassing

INHALATION GENERICS

- ICOPre
  - Unveiling the fourth inhaler platform
  - New generic platform
  - Addressable market & competition
- ICORES
  - Our flagship inhaler for inhaled generics
  - Addressable market and competition
  - Then new agreement with Amneal
- ICOCap
  - Our collaboration with Stevanato Group
  - Addressable market & competition

Roundtable discussion with with Q&A

### 3. Inhaled innovation – Dr Orest Lastow, Roger Lassing

INNOVATIVE INHALATION PROJECTS

- ICOone platform
- Unmet medical need addressed by inhalation therapy
  - Inhaled oxytocin in PPH – Monash University (Pete Lambert)
  - Inhaled covid-19 vaccine – ISR (Professor Ola Winqvist)
- Introducing the opportunities
  - Lung as target
  - Fast onset of action
  - Replacing injection
- Project status
- Addressable market for inhaled innovation

Roundtable discussion with Q&A

## Iconovo Pharma – Nordic sales – Johan Wäborg, Anna Gallon

- Generic Nordics sales organisation - rationale
- Go-to-market model
- Product portfolio and unique position
- Setup of Iconovo Pharma
- The market opportunity
  - Addressable market
  - Financial Targets and Timelines

**Roundtable discussion with Q&A**

## 4. Summary, corporate strategy, and future direction – Johan Wäborg, Anna Gallon

- Finance and shareholders
- Direction and opportunities to enhance value
- Summary

**Open Q&A session**

**Closing remarks – Gunnar Gårdemyr (Chairman of the Board)**